医学
败血症
共病
重症监护室
内科学
回顾性队列研究
静脉注射免疫球蛋白
病历
疾病
儿科
抗体
免疫学
作者
Milena Tocut,Tamara Kolitz,Ora Shovman,Yael Haviv,Mona Boaz,Shira Laviel,Stav Debi,Mona Nama,Amir Akria,Yehuda Shoenfeld,Arie Soroksky,Gisele Zandman‐Goddard
标识
DOI:10.1016/j.autrev.2022.103205
摘要
To evaluate the outcomes of hospitalized patients in two intensive care units (ICU) treated with intravenous immunoglobulin (IVIg) added to standard-of-care therapy. The indications for IVIg therapy were sepsis or autoimmune disease.We conducted a retrospective study involving adult patients with sepsis and autoimmune diseases, who received IVIg in the ICU at Wolfson and Sheba Medical Centers. A predefined chart was compiled on Excel to include a complete demographic collection, patient comorbidities, chronic medication use, disease severity scores (Charlson Comorbidity Index; SOFA and APACHE II index scores), indication and dosage of IVIg administration, duration of hospitalization and mortality rates.Patients (n - 111) were divided into 2 groups: patients with sepsis only (n-67) and patients with autoimmune disease only (n-44). Septic patients had a shorter ICU stay, received IVIg early, and had reduced mortality if treated with high dose IVIg. Patients with autoimmune diseases did not have a favorable outcome despite IVIg treatment. In this group, IVIg was administered later than in the sepsis group.IVIg therapy improved the outcomes for ICU patients with sepsis.
科研通智能强力驱动
Strongly Powered by AbleSci AI